Fulltext

Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF

Kuhle, Jens ; Lindberg, Raija ; Regeniter, Axel ; Mehling, Matthias ; Hoffmann, Francine ; Reindl, Markus ; Berger, Thomas ; Radue, Ernst ; Leppert, David ; Kappos, Ludwig

In: Journal of Neurology, 2007, vol. 254, no. 2, p. 160-168

Ajouter à la liste personnelle
    Titre
    • Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF
    Auteur
    • Kuhle, Jens. Dept. of Neurology, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland
    • Lindberg, Raija. Dept. of Neurology, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland
    • Regeniter, Axel. Clinical Chemistry Laboratory, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland
    • Mehling, Matthias. Dept. of Neurology, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland
    • Hoffmann, Francine. Dept. of Neurology, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland
    • Reindl, Markus. Clinical Dept. of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria
    • Berger, Thomas. Clinical Dept. of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria
    • Radue, Ernst. Dept. of Neuroradiology, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland
    • Leppert, David. Dept. of Neurology, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland
    • Kappos, Ludwig. Dept. of Neurology, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Journal of Neurology, 2007, vol. 254, no. 2, p. 160-168. Steinkopff-Verlag; www.steinkopff.springer.de
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:311435
    Summary
    Objective: We investigated the correlation of anti-myelin oligodendrocyte glycoprotein- (anti-MOG) and anti-myelin basic protein antibodies (anti-MBP) in serum of CIS patients with inflammatory signs in MRI and in CSF and, as previously suggested, the incidence of more frequent and rapid progression to clinically definite MS (CDMS). Methods: 133 CIS patients were analysed for anti-MOG and anti-MBP (Western blot). Routine CSF and cranial MRI (quantitatively and qualitatively) measures were analyzed. 55 patients had a follow-up of at least 12 months or until conversion to CDMS. Results: Patients with anti-MOG and anti-MBP had an increased intrathecal IgG production and CSF white blood cell count (p = 0.048 and p = 0.036). When anti-MBP alone, or both antibodies were present the cranial MRI showed significantly more T2 lesions (p = 0.007 and p = 0.01, respectively). There was a trend for more lesion dissemination in anti-MBP positive patients (p = 0.076). Conversely, anti-MOG- and/or anti-MBP failed to predict conversion to CDMS in our follow-up group (n = 55). Only in female patients with at least one MRI lesion (n = 34) did the presence of anti-MOG correlate with more frequent (p = 0.028) and more rapid (p = 0.0209) transition to CDMS. Conclusions: Presence of anti-MOG or anti-MBP or both was not significantly associated with conversion to CDMS in our CIS cohort. However, patients with anti-MOG and anti-MBP had higher lesion load and more disseminated lesions in cranial MRI as well as higher values for CSF leucocytes and intrathecal IgG production. Our data support a correlation of anti-MOG and anti-MBP to inflammatory signs in MRI and CSF. The prognostic value of these antibodies for CDMS, however, seems to be less pronounced than previously reported